SRPT
NASDAQ · Biotechnology
Sarepta Therapeutics Inc
$17.53
+0.57 (+3.36%)
Financial Highlights (FY 2026)
Revenue
2.35B
Net Income
-762,284,836
Gross Margin
69.3%
Profit Margin
-32.5%
Rev Growth
+33.1%
D/E Ratio
0.73
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.3% | 69.3% | 47.1% | 47.1% |
| Operating Margin | -31.1% | -28.0% | -17.1% | -14.3% |
| Profit Margin | -32.5% | -30.8% | -19.6% | -22.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.35B | 1.77B | 549.72M | 591.13M |
| Gross Profit | 1.63B | 1.22B | 259.01M | 278.52M |
| Operating Income | -729,787,485 | -493,581,375 | -94,265,427 | -84,661,399 |
| Net Income | -762,284,836 | -515,560,496 | -107,586,925 | -130,794,558 |
| Gross Margin | 69.3% | 69.3% | 47.1% | 47.1% |
| Operating Margin | -31.1% | -28.0% | -17.1% | -14.3% |
| Profit Margin | -32.5% | -30.8% | -19.6% | -22.1% |
| Rev Growth | +33.1% | +33.1% | +15.5% | +15.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 389.49M | 389.49M | 546.75M | 554.20M |
| Total Equity | 535.89M | 535.89M | 760.00M | 879.60M |
| D/E Ratio | 0.73 | 0.73 | 0.72 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -726,906,604 | -518,945,873 | -125,300,242 | -123,582,652 |
| Free Cash Flow | — | — | -79,607,758 | -118,891,652 |